Brazil approves first generic semaglutide pen after Ozempic patent expiry

Semaglutide just hit a new milestone in Brazil. The country approved its first generic semaglutide pen, right after the Ozempic patent expired. This opens the door for more labs to enter the field and ramps up competition in peptide research.

Semaglutide has been a hot topic for researchers worldwide, mainly for its role as a GLP-1 receptor agonist. Now, with generics available, Brazilian researchers get easier access to this peptide for their studies. Expect more data, more experiments, and way more innovation.

Key points:

Researchers interested in semaglutide can now explore new research angles without the old price and supply barriers. This could accelerate studies on everything from peptide stability to delivery mechanisms. It also gives sourcing teams more flexibility—no more waiting on single suppliers or overpaying for branded versions.

If you’re looking to source semaglutide or want to see which vendors now offer the generic, head over to the semaglutide page for details. Our vendor directory is also a solid place to keep an eye on new suppliers entering the scene.

Brazil’s move signals a shift in peptide accessibility. More research, more progress. That’s the real win.